Understanding the role of long-acting muscarinic antagonists in asthma treatment
Annals of Allergy, Asthma & Immunology
April 2022 Volume 128, Issue 4 Pages 352-360 CME Review
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Physicians involved in providing patient care in the field of allergy/asthma/immunology
Learning Objectives
At the conclusion of this activity, participants should be able to
- Describe the mechanisms of action of long-acting muscarinic antagonists (LAMA).
- Discuss where LAMAs fit in the clinical treatment of asthma.
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance